CUSIP 88322Q108 · who reports it, how much, and how much it matters to them
27 of the 720 hedge fund managers we track reported shares of TG Therapeutics, Inc. (Nasdaq: TGTX) on Form 13F for 30 June 2026. Between them they reported USD 555m. The largest position belongs to D. E. Shaw & Co., at USD 187m. The manager with the most riding on it is M28 Capital Management, where it is 10.3% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | D. E. Shaw & Co.15 funds on PPLI.com | USD 187m | 0.1% |
| 2 | Two Sigma Investments35 funds on PPLI.com | USD 136m | 0.1% |
| 3 | Renaissance Technologies13 funds on PPLI.com | USD 37m | 0.1% |
| 4 | Citadel Advisors32 funds on PPLI.com | USD 30m | 0.0% |
| 5 | Bridgewater Associates45 funds on PPLI.com | USD 24m | 0.1% |
| 6 | 683 Capital Management2 funds on PPLI.com | USD 21m | 1.1% |
| 7 | Weiss Asset Management5 funds on PPLI.com | USD 21m | 0.2% |
| 8 | Millennium Management6 funds on PPLI.com | USD 15m | 0.0% |
| 9 | POINT72 Asset Management17 funds on PPLI.com | USD 15m | 0.0% |
| 10 | Walleye Capital8 funds on PPLI.com | USD 10m | 0.0% |
| 11 | Squarepoint Ops7 funds on PPLI.com | USD 9.2m | 0.0% |
| 12 | Exome Asset Management2 funds on PPLI.com | USD 9.1m | 5.6% |
| 13 | Exoduspoint Capital Management7 funds on PPLI.com | USD 9m | 0.1% |
| 14 | Aquatic Capital Management3 funds on PPLI.com | USD 5.5m | 0.2% |
| 15 | Tudor Investment Corporation10 funds on PPLI.com | USD 5.2m | 0.0% |
| 16 | M28 Capital Management1 fund on PPLI.com | USD 4.9m | 10.3% |
| 17 | Edgestream Partners5 funds on PPLI.com | USD 3.8m | 0.1% |
| 18 | Capital Fund Management S.A.12 funds on PPLI.com | USD 3.8m | 0.0% |
| 19 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 3.6m | 0.0% |
| 20 | Verition Fund Management3 funds on PPLI.com | USD 2m | 0.0% |
| 21 | Brevan Howard Capital Management39 funds on PPLI.com | USD 1.4m | 0.0% |
| 22 | Capstone Investment Advisors25 funds on PPLI.com | USD 693,000 | 0.0% |
| 23 | Engineers Gate Manager1 fund on PPLI.com | USD 589,000 | 0.0% |
| 24 | Fora Capital1 fund on PPLI.com | USD 457,000 | 0.0% |
| 25 | Marshall Wace LLP84 funds on PPLI.com | USD 316,000 | 0.0% |
| 26 | CIBC Asset Management69 funds on PPLI.com | USD 263,000 | 0.0% |
| 27 | Fulcrum Asset Management LLP7 funds on PPLI.com | USD 10,921 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | M28 Capital Management | USD 4.9m | 10.3% |
| 2 | Exome Asset Management | USD 9.1m | 5.6% |
| 3 | 683 Capital Management | USD 21m | 1.1% |
| 4 | Weiss Asset Management | USD 21m | 0.2% |
| 5 | Aquatic Capital Management | USD 5.5m | 0.2% |
| 6 | Edgestream Partners | USD 3.8m | 0.1% |
| 7 | Two Sigma Investments | USD 136m | 0.1% |
| 8 | Bridgewater Associates | USD 24m | 0.1% |
| 9 | D. E. Shaw & Co. | USD 187m | 0.1% |
| 10 | Exoduspoint Capital Management | USD 9m | 0.1% |
TG Therapeutics, Inc. trades under the symbol TGTX on the Nasdaq. Its CUSIP, the code used on Form 13F, is 88322Q108.
27 of the 720 hedge fund managers PPLI.com tracks reported TG Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by D. E. Shaw & Co. (USD 187m), Two Sigma Investments (USD 136m), Renaissance Technologies (USD 37m), Citadel Advisors (USD 30m) and Bridgewater Associates (USD 24m).
27 managers in our coverage reported it, and between them they run 484 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
M28 Capital Management, where the position was 10.3% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with TG Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.